Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mori, M.
Right arrow Articles by Hattori, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mori, M.
Right arrow Articles by Hattori, T.
NEUROLOGY 2007;68:1144-1146
© 2007 American Academy of Neurology

Intravenous immunoglobulin therapy for Miller Fisher syndrome

Masahiro Mori, MD, Satoshi Kuwabara, MD, Toshio Fukutake, MD and Takamichi Hattori, MD

From the Department of Neurology, Graduate School of Medicine, Chiba University, Inohana, Chuo-ku, Chiba, Japan (M.M., S.K., T.H.); and Department of Neurology, Kameda Medical Center, Higashi-cho, Kamogawa-shi, Chiba, Japan (T.F.).

Address correspondence and reprint requests to Dr. Masahiro Mori, Department of Neurology, Graduate School of Medicine, Chiba University, 1-8-1, Inohana, Chuo-ku, Chiba, 260-8670 Japan; e-mail: morim{at}faculty.chiba-u.jp

We analyzed clinical recovery of 92 patients with Miller Fisher syndrome who had been treated with IV immunoglobulin (IVIg; n = 28), plasmapheresis (n = 23), and no immune treatment (n = 41). IVIg slightly hastened the amelioration of ophthalmoplegia and ataxia, but the times of the disappearances of those symptoms were similar among three groups. In Miller Fisher syndrome, IVIg and plasmapheresis seem not to have influenced patients' outcomes, presumably because of good natural recovery.

Additional material related to this article can be found on the Neurology Web site. Go to www.neurology.org and scroll down the Table of Contents for the April 3 issue to find the title link for this article.

Supported in part by a Neuroimmunological Disease Research Committee grant from the Ministry of Health, Labor and Welfare, Japan.

Disclosure: The authors report no conflicts of interest.

Received June 14, 2006. Accepted in final form November 27, 2006.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2007 by AAN Enterprises, Inc.